Mark Ellison brings more than 20 years of experience in the pharmaceutical industry developing products in the therapeutic areas of gastrointestinal, malignant disease, critical care, respiratory, wound healing and diabetes. His career focus has been in the areas of product development, regulatory strategy and compliance, quality assurance, clinical development and project management. Prior to Opiant, he was most recently Head of Technical Affairs at S.L.A. Pharma and has also held management positions at the Medicines and Healthcare products Regulatory Agency (MHRA), Link Pharmaceuticals, DMV International and Merck. Currently, he is the Director of Phax Pharma, a pharmaceutical consultancy. Dr. Ellison holds a BSc (Hons) in Pharmacy from the University of Portsmouth and a PhD in pharmaceutical technology from the University of Sunderland. He is a qualified pharmacist and member of the General Pharmaceutical Council in the U.K.